Harbour Biomed closed a multiyear discovery and development collaboration with Bristol Myers Squibb for multispecific antibodies, receiving roughly $90M upfront and potential milestones exceeding $1 billion. The deal builds on Harbour’s AI‑driven discovery platforms and comes amid a flurry of partnerships the biotech signed this year, including AI collaborations and licensing arrangements. Bristol Myers gains access to Harbour’s antibody engine and multispecific candidates. The agreements reflect Big Pharma’s continued strategy of buying or partnering for discovery scale and point to sustained deal activity at year‑end.